A Phase 2/3 interventional study of SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1 and SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2 in COVID-19, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 66 sites in 7 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 89th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 70 in phase 2/3, and was the 973rd registered.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,159 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
Sanofi has 6 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study are:
To assess the safety profile of the study vaccines in each study intervention group.
To assess the neutralizing antibody profile after primary series vaccination in SARS-CoV-2-naïve adults.
To demonstrate that a booster dose of monovalent or bivalent SARS-CoV-2 vaccine given to adults previously vaccinated with an authorized/approved COVID-19 vaccine induces an immune response that is non-inferior to the response induced by a twodose priming series with the monovalent vaccine, and superior to that observed immediately before booster.
The secondary objectives of the study are:
To assess the neutralizing and binding antibody profiles after primary series vaccination at pre-defined time points during the study.
To assess the neutralizing and binding antibody responses of booster vaccination.
To describe the occurrences of laboratory-confirmed symptomatic COVID19 after primary series and booster vaccination.
To describe the occurrences of serologically-confirmed SARS-CoV-2 infection after primary series vaccination.
The duration of each participant's participation in the study will be approximately:
Original Phase 2 part: 365 days postinjection 2 (ie, 386 days total). Supplemental Cohorts 1 and 2: 365 days post-booster injection (ie, 366 days total).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Aged 18 years or older on the day of inclusion. - -A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: Is of non-. To be considered of non-childbearing potential, a female mut be for at least 1 year or surgically sterile.
OR Is of childbearing potential and agrees to use an effective method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination (ie, second dose of primary series or booster injection). A participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 4 hours before any dose of study intervention. - - form has been signed and dated.
Able to attend all scheduled visits and to comply with all study procedures. SARS-CoV-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of SARS-CoV-2 antibodies (Original Phase 2 Cohort).
For persons living with (HIV), stable HIV infection determined by participant currently on antiretrovirals with > 200/mm3.
Does not intend to receive an authorized/approved COVID-19 vaccine from first vaccination to 3 weeks after the second vaccination despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment.
Supplemental cohorts: for participants originally enrolled in the Phase II cohort of the study, informed consent has to be signed and dated for transitioning to Supplemental Cohort 2.
Supplemental cohorts, Booster arms: received a complete primary vaccination series with an authorized/conditionally approved mRNA COVID-19 vaccine (mRNA-1273 [Moderna] or BNT162b2 [Pfizer/BioNTech]) or adenovirus-vectored COVID-19 vaccine (ChAdOx1 nCoV-19 [Oxford University/AstraZeneca] or Ad26.CoV2.S [J\&J/Janssen]), with the last dose administered a minimum of 4 months prior to inclusion but not longer than 10 months prior to inclusion.
Exclusion Criteria:
-Known systemic to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances.
Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures based on Investigator or designee's judgment.
Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on Investigator's judgment.
Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on Investigator's judgment.
Unstable acute or chronic illness that in the opinion of the Investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures.
Receipt of solid-organ or bone marrow transplants in the past 180 days. Receipt of anti-cancer chemotherapy in the last 90 days. Receipt of immunoglobulins, blood, or blood-derived products in the past 3 months.
Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]). A prospective participant should not be included in the trial until the condition has resolved or the febrile event has subsided. Receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention.
Applicable to Original Phase II Cohort, Supplemental Cohort 1 and Cohort 2 Comparator Group: Prior administration of a coronavirus vaccine (SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome [MERS-CoV]). Participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study trial period in another clinical study investigating a vaccine, drug, medical device, or medical procedure. Exclusion criterion for the Supplemental Cohort 1 and Cohort 2 comparator group: positive rapid diagnostic test for SARS-CoV-2 antibodies at time of enrollment.
Exclusion criterion for participants in Supplemental Cohort 2 who were primed as participant in the Original Phase II Cohort of the present study: Receipt of authorized/conditionally approved COVID-19 vaccine after enrollment in Original Phase 2 Cohort.
Exclusion criterion for all Booster groups: Documented virologically-confirmed SARS-CoV-2 infection (by NAAT) after first dose of primary immunization.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 injections of SARS-CoV-2 vaccine Formulation 1 at Day 1 and Day 22
Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1
2 injections of SARS-CoV-2 vaccine Formulation 2 at Day 1 and Day 22
Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2
2 injections of SARS-CoV-2 vaccine Formulation 3 Day 1 and Day 22
Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3
Participants who were previously vaccinated 4 to \< 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A
Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine or SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03
Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of bivalent (D614+B.1.351)-AS03 SARS-CoV-2 vaccine
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
Participants who were vaccinated 4 to \< 10 months prior with SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A
2 injections of monovalent (D614)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B
Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1
Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2
Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3
Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 Formulation 2
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 Formulation 3
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 (D614)-AS03, Dosage A
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 (B.1.351)-AS03
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 (D614)-AS03, Dosage B
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 (B.1.351)-AS03 Alternative Exploratory Formulation 1
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 (B.1.351)-AS03 Alternative Exploratory Formulation 2
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 (B.1.351)-AS03 Alternative Exploratory Formulation 3
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 (B.1.351)-AS03 Alternative Exploratory Formulation 4
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Also known as: rSP-COVID19 (D614+B.1.351)-AS03
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Immediate events were recorded to capture medically relevant unsolicited systemic AEs which occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination.
Time frame: Up to 30 minutes after each vaccination (Phase 2: Postdose on Days 1 and 22; Phase 3: Between 4 to 10 months after priming vaccine)
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Solicited Injection Site Reactions and Systemic Reactions
A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF, and were considered to be related to the study vaccine administered. An injection site reaction was an AR at and around the injection site of the study vaccine. Systemic AR were all ARs that were not injection site reactions.
Time frame: Up to 7 days after each vaccination (Phase 2: Postdose on Days 1 and 22; Phase 3: Between 4 to 10 months after priming vaccine)
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Unsolicited Adverse Events
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.
Time frame: Up to 21 days after each vaccination (Phase 2: Postdose on Days 1 and 22; Phase 3: Between 4 to 10 months after priming vaccine)
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs)
An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was 1 of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor could be appropriate. An MAAE was a new onset or a worsening of a condition that prompted the participant or participant's parent/guardian to seek unplanned medical advice at a physician's office or Emergency Department.
Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
Phase 2: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) D614G Strain at Day 1
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
Time frame: Pre-vaccination on Day 1
Phase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Day 36
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
Time frame: Day 36
Phase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
Time frame: Day 1 (pre-vaccination) and Day 36
Phase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36
Responders were participants who had baseline values below lower limit of quantification (LLOQ) with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point.
Time frame: Day 36
Phase 3: Cohorts 1 and 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Day 1
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
Time frame: Pre-vaccination on Day 1
Phase 3: Cohorts 1, 2 and Comparator: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at 14 Days Post-Vaccination
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
Time frame: Cohorts 1 and 2: 14 days post-vaccination on Day 1, Day 15; Comparator: 14 days post-vaccination on Day 22, Day 36
Phase 3: Comparator: Percentage of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Day 36
Responders were participants who had baseline values below LLOQ with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Percentages are rounded off to the tenth decimal place.
Time frame: Day 36
Phase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
Time frame: Post-vaccination on Days 22, 78, 134, 202, 292, and 387
Phase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 22, 78, 134, 202, 292, and 387
Phase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387
Responders were participants who had baseline values below LLOQ with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay).
Time frame: Post-vaccination on Days 22, 78, 134, 202, 292, and 387
Phase 2: Geometric Mean Concentration (GMC) of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 22, 36, 78, 134, 202, 292, and 387
Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-enzyme-linked immunosorbent assay (ELISA) and the results were expressed as geometric mean titers.
Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 22, 36, 78, 134, 202, 292, and 387
Phase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 78, 134, 202, 292, and 387
Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 22, 36, 78, 134, 202, 292, and 387
Phase 2: Number of Responders as Determined by Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 78, 134, 202, 292, and 387
Responders were participants who had baseline values below LLOQ with detectable antibody concentration above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay.
Time frame: Post-vaccination on Days 22, 36, 78, 134, 202, 292, and 387
Phase 3: Cohort 1: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 29, 91, 181, and 366
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
Time frame: Post-vaccination on Days 29, 91, 181, and 366
Phase 3: Cohort 1: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 15, 29, 91, 181, and 366
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 15, 29, 91, 181, and 366
Phase 3: Cohorts 1, 2 and Comparator: Percentage of Participants With Seroresponse Against SARS-CoV-2 D614G Strain and B.1.351 Variant at 14 Days Post-Vaccination
Seroresponse was defined as a \>=4-fold rise in serum neutralization titer against SARS-CoV-2 D614G strain and B.1.351 variant (post/pre) at Day 15 or Day 36 relative to Day 0 or Day 22. Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Percentages are rounded off to the tenth decimal place.
Time frame: Cohorts 1 and 2: 14 days post-vaccination on Day 1 (Day 15); Comparator: 14 days post-vaccination on Day 22 (Day 36)
Phase 3: Cohorts 1 and 2: Geometric Mean Concentration of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 15, 29, 91, 181, and 366
Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA and the results were expressed as geometric mean titers.
Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 15, 29, 91, 181, and 366
Phase 3: Cohorts 1 and 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 15, 29, 91, 181, and 366
Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 15, 29, 91, 181, and 366
Phase 3: Cohort 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 1, 15, 29, and 91
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 15, 29, and 91
Phase 3: Cohort 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 15, 29, and 91
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 15, 29, and 91
Phase 3: Comparator: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 1, 22, 36, 134, 202, 292, and 387
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 22, 36, 134, 202, 292, and 387
Phase 3: Comparator: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 22, 36, 134, 202, 292, and 387
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 22, 36, 134, 202, 292, and 387
Phase 3: Comparator: Geometric Mean Concentration of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 22, 36, 134, 202, 292, and 387
Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA and the results were expressed as geometric mean titers.
Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 22, 36, 134, 202, 292, and 387
Phase 3: Comparator: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 134, 202, 292, and 387
Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 22, 36, 134, 202, 292, and 387
Phase 3: Comparator: Percentage of Responders as Determined by Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 134, 202, 292, and 387
Responders were participants who had baseline values below LLOQ with detectable antibody concentration above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA. Percentages are rounded off to the tenth decimal place.
Time frame: Post-vaccination on Days 22, 36, 134, 202, 292, and 387
Phase 2: Percentage of Participants With Serologically-Confirmed SARS-CoV-2 Infection
Blood samples collected from participants were used for serological assessments in the study. Serologically-confirmed SARS-CoV-2 infection was defined as a positive result in a serum sample for antibodies specific to the nucleocapsid of SARS-CoV-2 detected by electrochemiluminescence immunoassay. Percentages are rounded off to the tenth decimal place.
Time frame: From first dose of study vaccine administration (Day 1) up to 387 days
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Laboratory-Confirmed Symptomatic COVID-19
Laboratory-confirmed SARS-CoV-2 infection was defined as a positive result for SARS-CoV-2 by nucleic acid amplification test (done by the central laboratory or locally) on at least 1 respiratory sample. Percentages are rounded off to the tenth decimal place.
Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Symptomatic COVID-19 Episodes Associated With Hospitalization
Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.
Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Severe Symptomatic COVID-19
Severe COVID-19 was defined as COVID-19 with any 1: Any clinical signs of severe illness measured at least on 2 occasions separated by 30 minutes, supplemental oxygen administration for \>1 hour, use of invasive or non-invasive ventilation or Extracorporeal Membrane Oxygenation, clinical diagnosis of respiratory failure, significant acute renal, hepatic, or neurologic dysfunction, shock (defined by systolic blood pressure ˂90 millimeter of mercury (mmHg), or diastolic blood pressure ˂60 mmHg or requiring vasopressors), admission to an intensive care unit, or death. Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.
Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Death Associated With Symptomatic COVID-19
Death associated with COVID-19 was defined as death in a participant with COVID-19 who died within 28 days of the first positive specimen date OR died more than 28 days after the first specimen date and COVID-19 was mentioned as an immediate or underlying cause of death on the death certificate. Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.
Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
The Phase 2 of study was conducted at 20 centers between 24 February 2021 and 01 May 2021. The Phase 3 of study was conducted at 110 centers between 29 July 2021 and 06 January 2023. CoV2 preS dTM= Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prefusion Spike delta TM, PBP=Pfizer/BioNTech Primed, MP= Moderna Primed, OUAP= Oxford University/AstraZeneca Primed, JJJP= J\&J/Janssen Primed and PP= Protein Primed.
| Milestone | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) | Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 241 | 239 | 242 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 199 | 204 | 204 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 42 | 35 | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 23 | 21 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 14 | 8 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) | Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 329 | 378 | 378 | 113 | 112 | 108 | 127 | 101 | 101 | 105 | 38 | 38 | 132 | 78 | 479 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 302 | 338 | 337 | 102 | 105 | 100 | 119 | 95 | 98 | 94 | 32 | 31 | 126 | 71 | 368 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 27 | 40 | 41 | 11 | 7 | 8 | 8 | 6 | 3 | 11 | 6 | 7 | 6 | 7 | 111 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 4 | 1 | 5 | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 1 | 0 | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 13 | 17 | 12 | 8 | 3 | 2 | 4 | 3 | 1 | 3 | 2 | 1 | 4 | 6 | 32 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 9 | 22 | 24 | 2 | 4 | 6 | 4 | 3 | 0 | 5 | 4 | 6 | 1 | 1 | 66 | 0 | 0 | 0 | 0 |
| Milestone | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) | Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 8 | 9 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 9 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
| titers | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Day 22 | 36.0 (29.4 to 44.2) | 39.6 (32.3 to 48.6) | 47.3 (37.8 to 59.1) |
| Day 78 | 467 (361 to 606) | 558 (438 to 711) | 569 (458 to 707) |
| Day 134 | 225 (160 to 318) | 249 (182 to 340) | 260 (190 to 358) |
| Day 202 | 254 (158 to 408) | 344 (208 to 570) | 259 (159 to 421) |
| Day 292 | 12145 (3643 to 40491) | 2518 (335 to 18928) | 804 (108 to 6014) |
| Day 387 | 17837 (9491 to 33522) | 46305 (24179 to 88677) | 8353 (1414 to 49336) |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Day 22: >=2-fold rise | 35 | 44 | 53 |
| Day 22: >=4-fold rise | 28 | 36 | 44 |
| Day 78: >=2-fold rise | 108 | 116 | 113 |
| Day 78: >=4-fold rise | 105 | 115 | 110 |
| Day 134: >=2-fold rise | 85 | 87 | 82 |
| Day 134: >=4-fold rise | 75 | 83 | 76 |
| Day 202: >=2-fold rise | 57 | 62 | 62 |
| Day 202: >=4-fold rise | 53 | 57 | 60 |
| Day 292: >=2-fold rise | 10 | 10 | 11 |
| Day 292: >=4-fold rise | 10 | 9 | 8 |
| Day 387: >=2-fold rise | 10 | 9 | 11 |
| Day 387: >=4-fold rise | 10 | 9 | 11 |
Responders were participants who had baseline values below LLOQ with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay).
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Day 22 | 35 | 44 | 53 |
| Day 78 | 108 | 116 | 113 |
| Day 134 | 85 | 87 | 82 |
| Day 202 | 57 | 62 | 62 |
| Day 292 | 10 | 10 | 11 |
| Day 387 | 10 | 9 | 11 |
Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-enzyme-linked immunosorbent assay (ELISA) and the results were expressed as geometric mean titers.
| titers | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Day 1 | 10.3 (9.54 to 11.1) | 9.99 (9.52 to 10.5) | 10.2 (9.77 to 10.7) |
| Day 22 | 103 (80.6 to 131) | 149 (119 to 187) | 228 (182 to 285) |
| Day 36 | 15533 (13000 to 18560) | 17176 (14468 to 20390) | 18003 (15039 to 21550) |
| Day 78 | 6572 (5469 to 7897) | 7526 (6112 to 9267) | 7133 (5848 to 8700) |
| Day 134 | 2750 (2104 to 3594) | 2977 (2305 to 3846) | 2696 (2064 to 3521) |
| Day 202 | 1414 (983 to 2033) | 1961 (1369 to 2809) | 1438 (978 to 2113) |
| Day 292 | 40589 (10633 to 155000) | 9247 (1625 to 52615) | 5557 (1183 to 26116) |
| Day 387 | 61087 (40242 to 92728) | 58674 (12370 to 278000) | 16234 (3146 to 83760) |
Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Day 22: >=2-fold rise | 141 | 155 | 161 |
| Day 22: >=4-fold rise | 117 | 136 | 156 |
| Day 36: >=2-fold rise | 159 | 160 | 165 |
| Day 36: >=4-fold rise | 158 | 160 | 165 |
| Day 78: >=2-fold rise | 121 | 124 | 124 |
| Day 78: >=4-fold rise | 121 | 124 | 124 |
| Day 134: >=2-fold rise | 101 | 109 | 100 |
| Day 134: >=4-fold rise | 101 | 109 | 100 |
| Day 202: >=2-fold rise | 85 | 91 | 86 |
| Day 202: >=4-fold rise | 85 | 91 | 85 |
| Day 292: >=2-fold rise | 11 | 12 | 14 |
| Day 292: >=4-fold rise | 11 | 12 | 14 |
| Day 387: >=2-fold rise | 10 | 10 | 13 |
| Day 387: >=4-fold rise | 10 | 10 | 13 |
Responders were participants who had baseline values below LLOQ with detectable antibody concentration above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay.
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Day 22 | 139 | 154 | 161 |
| Day 36 | 159 | 160 | 165 |
| Day 78 | 121 | 124 | 124 |
| Day 134 | 101 | 109 | 100 |
| Day 202 | 85 | 91 | 86 |
| Day 292 | 11 | 12 | 14 |
| Day 387 | 10 | 10 | 13 |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
| titers | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|
| Day 29: D614G | 5795 (5222 to 6432) | 5743 (4668 to 7065) | 4869 (4113 to 5764) | 4400 (3566 to 5430) |
| Day 29: B.1.351 | 2078 (1844 to 2342) | 1726 (1355 to 2198) | 1790 (1452 to 2207) | 1390 (1095 to 1764) |
| Day 91: D614G | 4623 (4037 to 5295) | 4879 (3774 to 6308) | 2704 (2065 to 3541) | 2509 (1954 to 3223) |
| Day 91: B.1.351 | 1522 (1304 to 1776) | 1254 (920 to 1711) | 949 (702 to 1281) | 711 (540 to 936) |
| Day 181: D614G | 7502 (6161 to 9135) | 10068 (6940 to 14605) | 2658 (1834 to 3852) | 5649 (3695 to 8635) |
| Day 181: B.1.351 | 2328 (1827 to 2966) | 3217 (2073 to 4992) | 1035 (650 to 1648) | 1853 (1095 to 3134) |
| Day 366: D614G | 10224 (8101 to 12903) | 10567 (6608 to 16898) | 2940 (1779 to 4858) | 6314 (3847 to 10361) |
| Day 366: B.1.351 | 3419 (2572 to 4545) | 3349 (1929 to 5812) | 942 (533 to 1664) | 2233 (1267 to 3937) |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
| Participants | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|
| D614G; Day 15: >=2-fold rise | 263 | 86 | 95 | 70 |
| D614G; Day 15: >=4-fold rise | 252 | 70 | 87 | 66 |
| D614G; Day 29: >=2-fold rise | 266 | 91 | 97 | 73 |
| D614G; Day 29: >=4-fold rise | 250 | 79 | 87 | 68 |
| D614G; Day 91: >=2-fold rise | 208 | 74 | 67 | 62 |
| D614G; Day 91: >=4-fold rise | 187 | 57 | 58 | 56 |
| D614G; Day 181: >=2-fold rise | 167 | 50 | 54 | 51 |
| D614G; Day 181: >=4-fold rise | 149 | 44 | 42 | 41 |
| D614G; Day 366: >=2-fold rise | 141 | 38 | 33 | 31 |
| D614G; Day 366: >=4-fold rise | 129 | 34 | 28 | 31 |
| B.1.351; Day 15: >=2-fold rise | 258 | 76 | 109 | 78 |
| B.1.351; Day 15: >=4-fold rise | 246 | 67 | 103 | 76 |
| B.1.351; Day 29: >=2-fold rise | 261 | 79 | 109 | 83 |
| B.1.351; Day 29: >=4-fold rise | 245 | 70 | 103 | 80 |
| B.1.351; Day 91: >=2-fold rise | 203 | 64 | 75 | 68 |
| B.1.351; Day 91: >=4-fold rise | 189 | 54 | 67 | 66 |
| B.1.351; Day 181: >=2-fold rise | 162 | 38 | 59 | 54 |
| B.1.351; Day 181: >=4-fold rise | 145 | 38 | 51 | 46 |
| B.1.351; Day 366: >=2-fold rise | 137 | 32 | 36 | 34 |
| B.1.351; Day 366: >=4-fold rise | 127 | 30 | 34 | 30 |
Seroresponse was defined as a \>=4-fold rise in serum neutralization titer against SARS-CoV-2 D614G strain and B.1.351 variant (post/pre) at Day 15 or Day 36 relative to Day 0 or Day 22. Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Percentages are rounded off to the tenth decimal place.
| percentage of participants | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D614G | 90.6 (86.6 to 93.8) | 73.7 (68.4 to 78.4) | 75.6 (70.5 to 80.2) | 71.4 (61.4 to 80.1) | 72.8 (62.6 to 81.6) | 63.7 (53.0 to 73.6) | 86.1 (77.8 to 92.2) | 89.7 (81.3 to 95.2) | 89.8 (81.5 to 95.2) | 88.0 (78.4 to 94.4) | 58.1 (39.1 to 75.5) | 78.8 (61.1 to 91.0) | 84.8 (76.2 to 91.3) | 90.6 (80.7 to 96.5) | 99.0 (97.1 to 99.8) |
| B.1.351 | 92.5 (88.6 to 95.3) | 83.3 (78.6 to 87.3) | 82.9 (78.1 to 87.0) | 84.8 (75.0 to 91.9) | 83.3 (73.6 to 90.6) | 80.0 (69.9 to 87.9) | 90.4 (83.4 to 95.1) | 95.4 (88.6 to 98.7) | 96.7 (90.7 to 99.3) | 93.8 (86.2 to 98.0) | 75.9 (56.5 to 89.7) | 77.4 (58.9 to 90.4) | 85.9 (77.4 to 92.0) | 90.6 (80.7 to 96.5) | 86.6 (82.1 to 90.3) |
Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA and the results were expressed as geometric mean titers.
| titers | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 1888 (1687 to 2114) | 3032 (2621 to 3507) | 2580 (2228 to 2987) | 3236 (2729 to 3839) | 3285 (2534 to 4259) | 3505 (2747 to 4471) | 993 (781 to 1262) | 564 (427 to 747) | 537 (420 to 687) | 608 (457 to 809) | 2290 (1068 to 4908) | 996 (491 to 2021) | 1357 (1004 to 1834) | 969 (688 to 1365) |
| Day 15 | 26710 (24337 to 29314) | 36428 (33227 to 39938) | 30892 (27925 to 34174) | 27390 (23220 to 32309) | 43611 (35852 to 53049) | 34704 (29398 to 40968) | 21654 (18927 to 24775) | 23775 (19137 to 29537) | 28783 (24417 to 33930) | 21758 (18254 to 25935) | 31067 (24221 to 39849) | 34534 (26146 to 45614) | 65824 (57576 to 75254) | 77057 (61772 to 96125) |
| Day 29 | 20212 (18487 to 22097) | 33416 (30407 to 36723) | 27083 (24480 to 29964) | 23079 (19417 to 27431) | 48428 (39336 to 59623) | 41018 (34290 to 49065) | 13305 (11657 to 15186) | 16401 (13253 to 20296) | 17729 (14944 to 21034) | 14014 (11798 to 16647) | 29315 (22236 to 38647) | 24388 (17369 to 34243) | 60707 (52764 to 69845) | 65974 (53800 to 80902) |
| Day 91 | 18845 (16780 to 21165) | 29384 (25972 to 33244) | 23908 (20860 to 27402) | 20758 (16506 to 26107) | 37791 (29062 to 49140) | 35363 (28656 to 43639) | 9792 (8093 to 11849) | 10365 (8105 to 13255) | 13189 (10078 to 17261) | 9032 (7387 to 11043) | 18463 (13497 to 25255) | 16236 (9684 to 27219) | 41282 (34967 to 48736) | 40566 (32032 to 51373) |
| Day 181 | 20073 (17076 to 23596) | 20450 (18029 to 23195) | 18628 (16117 to 21530) | 25701 (17854 to 36998) | 25615 (20346 to 32248) | 24500 (19714 to 30448) | 7281 (5366 to 9880) | 8665 (6100 to 12311) | 10649 (7312 to 15510) | 12342 (8420 to 18092) | 11275 (7727 to 16451) | 19231 (12448 to 29712) | 21387 (17825 to 25661) | 20803 (16151 to 26794) |
| Day 366 | 41232 (28233 to 60218) | 19545 (17037 to 22422) | 19989 (17351 to 23028) | 32368 (16026 to 65374) | 25800 (20031 to 33232) | 19848 (15543 to 25345) | — | 10382 (6531 to 16505) | 10937 (6565 to 18220) | 14545 (4542 to 46582) | 12176 (8897 to 16664) | 12002 (8266 to 17425) | 32168 (25602 to 40417) | 33194 (24774 to 44476) |
Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
| Participants | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 15: >=2-fold rise | 287 | 276 | 292 | 94 | 84 | 87 | 114 | 92 | 92 | 88 | 24 | 29 | 108 | 69 |
| Day 15: >=4-fold rise | 265 | 234 | 265 | 72 | 73 | 69 | 106 | 85 | 90 | 84 | 19 | 28 | 103 | 67 |
| Day 29: >=2-fold rise | 285 | 278 | 285 | 93 | 87 | 87 | 111 | 92 | 90 | 91 | 24 | 27 | 115 | 69 |
| Day 29: >=4-fold rise | 253 | 243 | 254 | 71 | 75 | 74 | 96 | 85 | 86 | 84 | 19 | 27 | 109 | 66 |
| Day 91: >=2-fold rise | 227 | 210 | 217 | 73 | 70 | 76 | 82 | 61 | 59 | 79 | 17 | 23 | 105 | 65 |
| Day 91: >=4-fold rise | 197 | 183 | 184 | 60 | 62 | 58 | 69 | 57 | 56 | 72 | 14 | 22 | 98 | 62 |
| Day 181: >=2-fold rise | 175 | 189 | 193 | 43 | 63 | 59 | 59 | 53 | 49 | 56 | 14 | 20 | 98 | 62 |
| Day 181: >=4-fold rise | 146 | 160 | 167 | 38 | 55 | 48 | 45 | 45 | 40 | 51 | 11 | 17 | 89 | 59 |
| Day 366: >=2-fold rise | 27 | 174 | 184 | 15 | 62 | 49 | — | 26 | 27 | 9 | 12 | 17 | 83 | 53 |
| Day 366: >=4-fold rise | 26 | 147 | 165 | 13 | 56 | 37 | — | 23 | 23 | 7 | 11 | 14 | 77 | 52 |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
| titers | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1: D614G | 678 (558 to 824) | 579 (478 to 701) | 1107 (816 to 1503) | 1347 (977 to 1858) | 137 (98.0 to 193) | 134 (95.7 to 186) | 1188 (567 to 2490) | 447 (217 to 921) | 274 (182 to 413) | 159 (97.4 to 260) |
| Day 1: B.1.351 | 176 (142 to 217) | 149 (120 to 184) | 258 (182 to 364) | 296 (207 to 424) | 43.3 (32.0 to 58.5) | 36.8 (28.8 to 47.1) | 345 (167 to 714) | 122 (55.3 to 268) | 97.7 (68.0 to 140) | 70.3 (47.9 to 103) |
| Day 15: D614G | 9995 (8976 to 11129) | 8430 (7572 to 9386) | 14240 (11257 to 18013) | 12522 (10368 to 15123) | 5536 (4436 to 6910) | 5855 (4669 to 7344) | 11005 (7533 to 16078) | 11624 (8086 to 16710) | 22457 (19123 to 26374) | 25002 (18441 to 33897) |
| Day 15: B.1.351 | 7021 (6262 to 7873) | 4900 (4370 to 5494) | 9449 (7376 to 12104) | 6581 (5340 to 8111) | 4610 (3689 to 5760) | 3099 (2386 to 4026) | 6872 (4482 to 10537) | 5057 (3416 to 7488) | 7452 (6212 to 8939) | 13300 (9817 to 18018) |
| Day 29: D614G | 14065 (12399 to 15954) | 10885 (9664 to 12261) | 16286 (12808 to 20710) | 16874 (13763 to 20688) | 6320 (4941 to 8083) | 6370 (5014 to 8093) | 9711 (6526 to 14450) | 9521 (6555 to 13828) | 16032 (13535 to 18989) | 16425 (12103 to 22291) |
| Day 29: B.1.351 | 8947 (7845 to 10203) | 6045 (5307 to 6886) | 10264 (7924 to 13296) | 8139 (6470 to 10239) | 4736 (3680 to 6096) | 3103 (2340 to 4115) | 6028 (3889 to 9342) | 4007 (2553 to 6290) | 7185 (5841 to 8838) | 12712 (9376 to 17234) |
| Day 91: D614G | 11037 (9530 to 12782) | 8523 (7284 to 9973) | 13701 (10206 to 18392) | 12424 (9586 to 16103) | 3620 (2680 to 4891) | 3981 (2812 to 5637) | 5797 (3725 to 9024) | 5880 (3125 to 11064) | 14498 (11931 to 17618) | 13641 (9766 to 19055) |
| Day 91: B.1.351 | 6557 (5617 to 7654) | 4359 (3673 to 5172) | 8141 (5982 to 11080) | 5474 (4176 to 7175) | 2456 (1792 to 3364) | 2029 (1376 to 2993) | 3374 (2161 to 5269) | 2405 (1093 to 5295) | 6455 (5117 to 8143) | 8990 (6284 to 12861) |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
| Participants | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|
| D614G; Day 15: >=2-fold rise | 267 | 269 | 79 | 77 | 85 | 84 | 26 | 30 | 86 | 60 |
| D614G; Day 15: >=4-fold rise | 232 | 242 | 67 | 58 | 78 | 79 | 18 | 26 | 84 | 58 |
| D614G; Day 29: >=2-fold rise | 272 | 283 | 83 | 76 | 84 | 83 | 22 | 28 | 89 | 58 |
| D614G; Day 29: >=4-fold rise | 240 | 251 | 74 | 67 | 80 | 80 | 15 | 23 | 85 | 56 |
| D614G; Day 91: >=2-fold rise | 199 | 208 | 69 | 70 | 57 | 51 | 16 | 20 | 81 | 57 |
| D614G; Day 91: >=4-fold rise | 175 | 187 | 57 | 54 | 55 | 48 | 12 | 16 | 78 | 53 |
| B.1.351; Day 15: >=2-fold rise | 275 | 269 | 77 | 79 | 85 | 88 | 28 | 28 | 88 | 62 |
| B.1.351; Day 15: >=4-fold rise | 249 | 247 | 70 | 68 | 83 | 88 | 22 | 24 | 85 | 58 |
| B.1.351; Day 29: >=2-fold rise | 278 | 277 | 81 | 79 | 86 | 87 | 28 | 26 | 95 | 62 |
| B.1.351; Day 29: >=4-fold rise | 258 | 261 | 75 | 70 | 84 | 87 | 20 | 25 | 92 | 58 |
| B.1.351; Day 91: >=2-fold rise | 212 | 207 | 69 | 68 | 56 | 56 | 22 | 21 | 87 | 58 |
| B.1.351; Day 91: >=4-fold rise | 195 | 197 | 62 | 60 | 56 | 53 | 16 | 17 | 80 | 55 |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
| titers | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|
| D614G: Day 1 | 20.3 (19.7 to 21.0) |
| D614G: Day 22 | 53.3 (44.6 to 63.8) |
| D614G: Day 36 | 3658 (3123 to 4286) |
| D614G: Day 134 | 1050 (743 to 1486) |
| D614G: Day 202 | 1685 (1142 to 2487) |
| D614G: Day 292 | 1943 (1294 to 2918) |
| D614G: Day 387 | 1973 (1344 to 2897) |
| B.1.351: Day 1 | 20.3 (19.7 to 20.8) |
| B.1.351: Day 22 | 29.4 (25.7 to 33.5) |
| B.1.351: Day 36 | 413 (346 to 493) |
| B.1.351: Day 134 | 496 (330 to 745) |
| B.1.351: Day 202 | 671 (441 to 1022) |
| B.1.351: Day 292 | 867 (560 to 1342) |
| B.1.351: Day 387 | 1033 (686 to 1555) |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
| Participants | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|
| D614G; Day 22: >=2-fold rise | 99 |
| D614G; Day 22: >=4-fold rise | 88 |
| D614G; Day 36: >=2-fold rise | 299 |
| D614G; Day 36: >=4-fold rise | 298 |
| D614G; Day 134: >=2-fold rise | 134 |
| D614G; Day 134: >=4-fold rise | 131 |
| D614G; Day 202: >=2-fold rise | 120 |
| D614G; Day 202: >=4-fold rise | 119 |
| D614G; Day 292: >=2-fold rise | 108 |
| D614G; Day 292: >=4-fold rise | 105 |
| D614G; Day 387: >=2-fold rise | 105 |
| D614G; Day 387: >=4-fold rise | 101 |
| B.1.351; Day 22: >=2-fold rise | 39 |
| B.1.351; Day 22: >=4-fold rise | 32 |
| B.1.351; Day 36: >=2-fold rise | 264 |
| B.1.351; Day 36: >=4-fold rise | 251 |
| B.1.351; Day 134: >=2-fold rise | 99 |
| B.1.351; Day 134: >=4-fold rise | 89 |
| B.1.351; Day 202: >=2-fold rise | 100 |
| B.1.351; Day 202: >=4-fold rise | 97 |
| B.1.351; Day 292: >=2-fold rise | 98 |
| B.1.351; Day 292: >=4-fold rise | 91 |
| B.1.351; Day 387: >=2-fold rise | 96 |
| B.1.351; Day 387: >=4-fold rise | 94 |
Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA and the results were expressed as geometric mean titers.
| titers | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|
| Day 1 | 10.7 (9.91 to 11.6) |
| Day 22 | 212 (183 to 246) |
| Day 36 | 24278 (21681 to 27185) |
| Day 134 | 6593 (4952 to 8779) |
| Day 202 | 6667 (4833 to 9197) |
| Day 292 | 6868 (4919 to 9587) |
| Day 387 | 7112 (5216 to 9697) |
Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
| Participants | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|
| Day 22: >=2-fold rise | 312 |
| Day 22: >=4-fold rise | 290 |
| Day 36: >=2-fold rise | 302 |
| Day 36: >=4-fold rise | 302 |
| Day 134: >=2-fold rise | 149 |
| Day 134: >=4-fold rise | 148 |
| Day 202: >=2-fold rise | 133 |
| Day 202: >=4-fold rise | 133 |
| Day 292: >=2-fold rise | 123 |
| Day 292: >=4-fold rise | 123 |
| Day 387: >=2-fold rise | 117 |
| Day 387: >=4-fold rise | 117 |
Responders were participants who had baseline values below LLOQ with detectable antibody concentration above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|
| Day 22 | 94.3 (91.2 to 96.5) |
| Day 36 | 99.7 (98.3 to 100) |
| Day 134 | 98.7 (95.5 to 99.8) |
| Day 202 | 99.3 (96.1 to 100) |
| Day 292 | 99.3 (95.9 to 100) |
| Day 387 | 99.2 (95.7 to 100) |
Blood samples collected from participants were used for serological assessments in the study. Serologically-confirmed SARS-CoV-2 infection was defined as a positive result in a serum sample for antibodies specific to the nucleocapsid of SARS-CoV-2 detected by electrochemiluminescence immunoassay. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Phase 2: Percentage of Participants With Serologically-Confirmed SARS-CoV-2 Infection | 12.1 (8.2 to 16.9) | 10.8 (7.2 to 15.5) | 14.1 (10.0 to 19.2) |
Laboratory-confirmed SARS-CoV-2 infection was defined as a positive result for SARS-CoV-2 by nucleic acid amplification test (done by the central laboratory or locally) on at least 1 respiratory sample. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Laboratory-Confirmed Symptomatic COVID-19 | 3.3 (1.4 to 6.5) | 1.7 (0.5 to 4.2) | 5.4 (2.9 to 9.0) | 14.0 (10.5 to 18.3) | 20.9 (16.9 to 25.4) | 23.5 (19.3 to 28.1) | 12.4 (6.9 to 19.9) | 10.8 (5.7 to 18.1) | 10.2 (5.2 to 17.5) | 24.4 (17.2 to 32.8) | 25.0 (16.9 to 34.7) | 29.0 (20.4 to 38.9) | 9.7 (4.8 to 17.1) | 0 (0 to 9.3) | 18.4 (7.7 to 34.3) | 18.9 (12.6 to 26.7) | 19.2 (11.2 to 29.7) | 8.2 (5.9 to 11.1) |
Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Symptomatic COVID-19 Episodes Associated With Hospitalization | 0 (0 to 1.5) | 0 (0 to 1.5) | 0 (0 to 1.5) | 0 (0 to 1.1) | 0 (0 to 1.0) | 0.3 (0 to 1.5) | 0 (0 to 3.2) | 0 (0 to 3.3) | 0 (0 to 3.4) | 0.8 (0 to 4.3) | 0 (0 to 3.6) | 0 (0 to 3.6) | 0 (0 to 3.5) | 0 (0 to 9.3) | 0 (0 to 9.3) | 0 (0 to 2.8) | 0 (0 to 4.6) | 0 (0 to 0.8) |
Severe COVID-19 was defined as COVID-19 with any 1: Any clinical signs of severe illness measured at least on 2 occasions separated by 30 minutes, supplemental oxygen administration for \>1 hour, use of invasive or non-invasive ventilation or Extracorporeal Membrane Oxygenation, clinical diagnosis of respiratory failure, significant acute renal, hepatic, or neurologic dysfunction, shock (defined by systolic blood pressure ˂90 millimeter of mercury (mmHg), or diastolic blood pressure ˂60 mmHg or requiring vasopressors), admission to an intensive care unit, or death. Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Severe Symptomatic COVID-19 | 0 (0 to 1.5) | 0 (0 to 1.5) | 0 (0 to 1.5) | 0 (0 to 1.1) | 0 (0 to 1.0) | 0.3 (0 to 1.5) | 0 (0 to 3.2) | 0 (0 to 3.3) | 0 (0 to 3.4) | 0 (0 to 2.9) | 0 (0 to 3.6) | 0 (0 to 3.6) | 0 (0 to 3.5) | 0 (0 to 9.3) | 0 (0 to 9.3) | 0.8 (0 to 4.1) | 0 (0 to 4.6) | 0 (0 to 0.8) |
Death associated with COVID-19 was defined as death in a participant with COVID-19 who died within 28 days of the first positive specimen date OR died more than 28 days after the first specimen date and COVID-19 was mentioned as an immediate or underlying cause of death on the death certificate. Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Death Associated With Symptomatic COVID-19 | 0 (0 to 1.5) | 0 (0 to 1.5) | 0 (0 to 1.5) | 0 (0 to 1.1) | 0 (0 to 1.0) | 0 (0 to 1.0) | 0 (0 to 3.2) | 0 (0 to 3.3) | 0 (0 to 3.4) | 0 (0 to 2.9) | 0 (0 to 3.6) | 0 (0 to 3.6) | 0 (0 to 3.5) | 0 (0 to 9.3) | 0 (0 to 9.3) | 0 (0 to 2.8) | 0 (0 to 4.6) | 0 (0 to 0.8) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Immediate events were recorded to capture medically relevant unsolicited systemic AEs which occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination.
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs) | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF, and were considered to be related to the study vaccine administered. An injection site reaction was an AR at and around the injection site of the study vaccine. Systemic AR were all ARs that were not injection site reactions.
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site reaction | 201 | 196 | 200 | 262 | 300 | 303 | 90 | 82 | 74 | 104 | 87 | 87 | 81 | 19 | 19 | 98 | 46 | 375 |
| Systemic reaction | 191 | 191 | 185 | 198 | 238 | 242 | 67 | 67 | 65 | 75 | 61 | 75 | 62 | 14 | 17 | 88 | 36 | 359 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Unsolicited Adverse Events | 88 | 81 | 91 | 76 | 106 | 96 | 29 | 18 | 22 | 34 | 27 | 35 | 16 | 7 | 7 | 25 | 11 | 199 |
An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was 1 of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor could be appropriate. An MAAE was a new onset or a worsening of a condition that prompted the participant or participant's parent/guardian to seek unplanned medical advice at a physician's office or Emergency Department.
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAE | 2 | 6 | 4 | 8 | 9 | 11 | 3 | 1 | 4 | 3 | 4 | 0 | 1 | 2 | 3 | 3 | 3 | 14 |
| AESI | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| MAAE | 42 | 48 | 59 | 80 | 106 | 117 | 28 | 25 | 19 | 31 | 24 | 29 | 19 | 7 | 7 | 42 | 32 | 110 |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
| titers | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Phase 2: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) D614G Strain at Day 1 | 20.0 (NA to NA) | 20.0 (NA to NA) | 20.0 (NA to NA) |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
| titers | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Phase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Day 36 | 2132 (1690 to 2688) | 2376 (1873 to 3015) | 2903 (2289 to 3683) |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| >=2-fold rise | 155 | 156 | 158 |
| >=4-fold rise | 154 | 154 | 157 |
Responders were participants who had baseline values below lower limit of quantification (LLOQ) with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point.
| Participants | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 |
|---|---|---|---|
| Phase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36 | 155 | 156 | 158 |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
| titers | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D614G | 320 (275 to 373) | 678 (558 to 824) | 579 (478 to 701) | 668 (537 to 830) | 1107 (816 to 1503) | 1347 (977 to 1858) | 265 (190 to 369) | 137 (98.0 to 193) | 134 (95.7 to 186) | 222 (155 to 318) | 1188 (567 to 2490) | 447 (217 to 921) | 274 (182 to 413) | 159 (97.4 to 260) |
| B.1.351 | 70.1 (60.3 to 81.4) | 176 (142 to 217) | 149 (120 to 184) | 122 (95.4 to 157) | 258 (182 to 364) | 296 (207 to 424) | 54.1 (41.4 to 70.7) | 43.3 (32.0 to 58.5) | 36.8 (28.8 to 47.1) | 42.6 (32.5 to 55.7) | 345 (167 to 714) | 122 (55.3 to 268) | 97.7 (68.0 to 140) | 70.3 (47.9 to 103) |
Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.
| titers | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D614G | 6964 (6268 to 7737) | 9995 (8976 to 11129) | 8430 (7572 to 9386) | 6347 (5207 to 7736) | 14240 (11257 to 18013) | 12522 (10368 to 15123) | 6257 (5313 to 7369) | 5536 (4436 to 6910) | 5855 (4669 to 7344) | 6875 (5587 to 8460) | 11005 (7533 to 16078) | 11624 (8086 to 16710) | 22457 (19123 to 26374) | 25002 (18441 to 33897) | 3611 (3086 to 4224) |
| B.1.351 | 2610 (2316 to 2942) | 7021 (6262 to 7873) | 4900 (4370 to 5494) | 2222 (1754 to 2814) | 9449 (7376 to 12104) | 6581 (5340 to 8111) | 2062 (1708 to 2489) | 4610 (3689 to 5760) | 3099 (2386 to 4026) | 2054 (1642 to 2568) | 6872 (4482 to 10537) | 5057 (3416 to 7488) | 7452 (6212 to 8939) | 13300 (9817 to 18018) | 413 (346 to 493) |
Responders were participants who had baseline values below LLOQ with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) |
|---|---|
| D614G | 99.3 (97.6 to 99.9) |
| B.1.351 | 91.0 (87.1 to 94.1) |
Collected over Phase 2 and Phase 3 Comparator: AEs data was collected from first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: AEs data was collected from first dose of study vaccine administration (Day 1) up to 366 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | 0/240 (0%) | 2/240 (0.8%) | 217/240 (90.4%) |
| Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | 0/240 (0%) | 6/240 (2.5%) | 215/240 (89.6%) |
| Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | 0/241 (0%) | 4/241 (1.7%) | 219/241 (90.9%) |
| Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | 0/328 (0%) | 8/328 (2.4%) | 281/328 (85.7%) |
| Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | 0/378 (0%) | 9/378 (2.4%) | 328/378 (86.8%) |
| Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | 0/375 (0%) | 11/375 (2.9%) | 331/375 (88.3%) |
| Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | 0/113 (0%) | 3/113 (2.7%) | 97/113 (85.8%) |
| Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | 0/111 (0%) | 1/111 (0.9%) | 88/111 (79.3%) |
| Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | 0/108 (0%) | 4/108 (3.7%) | 83/108 (76.9%) |
| Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | 0/127 (0%) | 3/127 (2.4%) | 115/127 (90.6%) |
| Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | 0/100 (0%) | 4/100 (4%) | 92/100 (92%) |
| Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | 0/100 (0%) | 0/100 (0%) | 97/100 (97%) |
| Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | 0/103 (0%) | 1/103 (1%) | 89/103 (86.4%) |
| Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | 0/38 (0%) | 2/38 (5.3%) | 21/38 (55.3%) |
| Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | 0/38 (0%) | 3/38 (7.9%) | 24/38 (63.2%) |
| Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | 0/132 (0%) | 3/132 (2.3%) | 112/132 (84.8%) |
| Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | 0/78 (0%) | 3/78 (3.8%) | 59/78 (75.6%) |
| Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) | 1/473 (0.2%) | 14/473 (3%) | 421/473 (89%) |
| Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351) | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351) | 0/9 (0%) | 1/9 (11.1%) | 8/9 (88.9%) |
| Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351) | 0/9 (0%) | 1/9 (11.1%) | 6/9 (66.7%) |
| Event | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) | Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anal AbscessInfections and infestations | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 0/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 0/38 | 0/38 | 0/132 | 0/78 | 0/473 | 1/4 | 0/8 | 0/9 | 0/9 |
| CholecystitisHepatobiliary disorders | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 1/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 1/103 | 0/38 | 0/38 | 0/132 | 0/78 | 0/473 | 1/4 | 0/8 | 0/9 | 0/9 |
| Motor Neurone DiseaseNervous system disorders | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 0/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 0/38 | 0/38 | 0/132 | 0/78 | 0/473 | 0/4 | 0/8 | 0/9 | 1/9 |
| AbscessInfections and infestations | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 0/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 0/38 | 0/38 | 0/132 | 0/78 | 0/473 | 0/4 | 0/8 | 1/9 | 0/9 |
| Periumbilical AbscessInfections and infestations | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 0/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 0/38 | 0/38 | 0/132 | 0/78 | 0/473 | 0/4 | 0/8 | 1/9 | 0/9 |
| Angina PectorisCardiac disorders | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 0/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 0/38 | 1/38 | 0/132 | 0/78 | 0/473 | 0/4 | 0/8 | 0/9 | 0/9 |
| Alcoholic SeizureNervous system disorders | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 0/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 1/38 | 0/38 | 0/132 | 0/78 | 0/473 | 0/4 | 0/8 | 0/9 | 0/9 |
| Cerebrovascular AccidentNervous system disorders | 0/240 | 1/240 | 0/241 | 0/328 | 1/378 | 0/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 0/38 | 1/38 | 0/132 | 0/78 | 0/473 | 0/4 | 0/8 | 0/9 | 0/9 |
| Diabetes MellitusMetabolism and nutrition disorders | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 0/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 0/38 | 1/38 | 0/132 | 0/78 | 0/473 | 0/4 | 0/8 | 0/9 | 0/9 |
| Ovarian AbscessInfections and infestations | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 0/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 1/38 | 0/38 | 0/132 | 0/78 | 0/473 | 0/4 | 0/8 | 0/9 | 0/9 |
| Event | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) | Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection Site PainGeneral disorders | 199/240 | 194/240 | 200/241 | 259/328 | 297/378 | 301/375 | 89/113 | 81/111 | 75/108 | 100/127 | 86/100 | 85/100 | 80/103 | 18/38 | 19/38 | 96/132 | 46/78 | 372/473 | 4/4 | 5/8 | 7/9 | 3/9 |
| HeadacheNervous system disorders | 141/240 | 134/240 | 134/241 | 130/328 | 167/378 | 165/375 | 47/113 | 50/111 | 39/108 | 45/127 | 48/100 | 55/100 | 37/103 | 10/38 | 10/38 | 51/132 | 20/78 | 278/473 | 2/4 | 3/8 | 6/9 | 3/9 |
| MalaiseGeneral disorders | 138/240 | 142/240 | 146/241 | 101/328 | 122/378 | 122/375 | 42/113 | 39/111 | 33/108 | 40/127 | 35/100 | 43/100 | 31/103 | 8/38 | 7/38 | 61/132 | 25/78 | 241/473 | 1/4 | 3/8 | 2/9 | 3/9 |
| MyalgiaMusculoskeletal and connective tissue disorders | 143/240 | 135/240 | 123/241 | 123/328 | 145/378 | 153/375 | 41/113 | 48/111 | 43/108 | 40/127 | 36/100 | 54/100 | 33/103 | 9/38 | 11/38 | 61/132 | 27/78 | 275/473 | 2/4 | 2/8 | 4/9 | 4/9 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 107/240 | 102/240 | 104/241 | 91/328 | 110/378 | 114/375 | 31/113 | 39/111 | 31/108 | 22/127 | 30/100 | 35/100 | 24/103 | 6/38 | 7/38 | 42/132 | 18/78 | 228/473 | 0/4 | 1/8 | 1/9 | 1/9 |
| ChillsGeneral disorders | 97/240 | 93/240 | 77/241 | 50/328 | 74/378 | 77/375 | 16/113 | 23/111 | 23/108 | 23/127 | 23/100 | 31/100 | 10/103 | 5/38 | 5/38 | 38/132 | 15/78 | 160/473 | 0/4 | 1/8 | 1/9 | 1/9 |
| Biliary ColicHepatobiliary disorders | 0/240 | 0/240 | 0/241 | 0/328 | 0/378 | 1/375 | 0/113 | 0/111 | 0/108 | 0/127 | 0/100 | 0/100 | 0/103 | 0/38 | 0/38 | 0/132 | 0/78 | 0/473 | 1/4 | 0/8 | 0/9 | 0/9 |
| Injection Site SwellingGeneral disorders | 40/240 | 39/240 | 37/241 | 32/328 | 37/378 | 25/375 | 10/113 | 7/111 | 4/108 | 24/127 | 8/100 | 5/100 | 6/103 | 0/38 | 3/38 | 11/132 | 3/78 | 72/473 | 0/4 | 1/8 | 0/9 | 0/9 |
| Injection Site ErythemaGeneral disorders | 28/240 | 41/240 | 26/241 | 32/328 | 23/378 | 19/375 | 8/113 | 7/111 | 4/108 | 22/127 | 8/100 | 9/100 | 5/103 | 1/38 | 3/38 | 9/132 | 2/78 | 77/473 | 0/4 | 0/8 | 0/9 | 0/9 |
| Covid-19Infections and infestations | 5/240 | 3/240 | 7/241 | 16/328 | 34/378 | 37/375 | 6/113 | 4/111 | 9/108 | 2/127 | 9/100 | 6/100 | 5/103 | 0/38 | 1/38 | 20/132 | 13/78 | 21/473 | 0/4 | 0/8 | 1/9 | 1/9 |
All Randomized set included all participants with a randomized group allocated by interactive response technology. Participants from the Original Cohort were included in the Booster Cohorts because these assessed separate objectives. To be eligible, participants in the Booster Cohorts were required to have received a primary series, as administered in the Original Cohort.
| Age, Categorical(Participants) | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) | Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 — <=18 years | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Phase 2 — Between 18 and 65 years | 195 | 196 | 196 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 587 |
| Phase 2 — >=65 years | 46 | 42 | 46 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 134 |
| Phase 3 — <=18 years | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 17 |
| Phase 3 — Between 18 and 65 years | 0 | 0 | 0 | 266 | 357 | 353 | 88 | 97 | 94 | 95 | 86 | 87 | 98 | 35 | 36 | 92 | 40 | 467 | 0 | 0 | 0 | 0 | 2291 |
| Phase 3 — >=65 years | 0 | 0 | 0 | 63 | 17 | 23 | 25 | 15 | 13 | 32 | 15 | 14 | 6 | 3 | 2 | 40 | 38 | 3 | 0 | 0 | 0 | 0 | 309 |
| Phase 3 - Exploratory — <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 3 - Exploratory — Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 9 | 8 | 28 |
| Phase 3 - Exploratory — >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Sex: Female, Male(Participants) | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) | Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 — Female | 123 | 114 | 122 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 359 |
| Phase 2 — Male | 118 | 125 | 120 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 363 |
| Phase 3 — Female | 0 | 0 | 0 | 181 | 208 | 199 | 68 | 60 | 64 | 59 | 42 | 48 | 63 | 19 | 20 | 64 | 38 | 215 | 0 | 0 | 0 | 0 | 1348 |
| Phase 3 — Male | 0 | 0 | 0 | 148 | 170 | 179 | 45 | 52 | 44 | 68 | 59 | 53 | 42 | 19 | 18 | 68 | 40 | 264 | 0 | 0 | 0 | 0 | 1269 |
| Phase 3 - Exploratory — Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 8 | 6 | 20 |
| Phase 3 - Exploratory — Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 1 | 3 | 10 |
| Race/Ethnicity, Customized(Participants) | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2 | Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3 | Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614) | Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351) | Phase 3: Comparator: CoV2 preS dTM-AS03 (D614) | Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351) | Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 — American Indian or Alaska Native | 22 | 24 | 20 | 5 | 5 | 6 | 2 | 6 | 2 | 0 | 0 | 0 | 1 | 4 | 2 | 20 | 14 | 15 | 0 | 0 | 0 | 0 | 148 |
| Phase 2 — Asian | 13 | 10 | 10 | 19 | 12 | 13 | 7 | 1 | 3 | 11 | 4 | 7 | 0 | 2 | 2 | 2 | 2 | 18 | 0 | 0 | 0 | 0 | 136 |
| Phase 2 — Black or African American | 14 | 23 | 20 | 15 | 54 | 61 | 3 | 16 | 32 | 2 | 3 | 2 | 5 | 16 | 10 | 7 | 2 | 52 | 0 | 0 | 0 | 0 | 337 |
| Phase 2 — Multiple | 5 | 2 | 4 | 1 | 6 | 6 | 1 | 3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 8 | 0 | 0 | 0 | 0 | 39 |
| Phase 2 — Native Hawaiian or Other Pacific Islander | 2 | 1 | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 10 |
| Phase 2 — White | 156 | 149 | 156 | 252 | 247 | 240 | 100 | 79 | 61 | 104 | 92 | 87 | 99 | 15 | 21 | 80 | 37 | 372 | 0 | 0 | 0 | 0 | 2347 |
| Phase 2 — Missing | 29 | 30 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 89 |
| Phase 2 — Not Reported | 0 | 0 | 0 | 33 | 44 | 49 | 0 | 1 | 6 | 10 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 3 | 4 | 7 | 8 | 9 | 179 |
| Phase 2 — Unknown | 0 | 0 | 0 | 4 | 8 | 2 | 0 | 6 | 3 | 0 | 1 | 2 | 0 | 0 | 1 | 23 | 22 | 10 | 0 | 1 | 1 | 0 | 84 |
| Phase 3 — American Indian or Alaska Native | 0 | 0 | 0 | 5 | 5 | 6 | 2 | 6 | 2 | 0 | 0 | 0 | 1 | 4 | 2 | 20 | 14 | 15 | 0 | 0 | 0 | 0 | 82 |
| Phase 3 — Asian | 0 | 0 | 0 | 19 | 12 | 13 | 7 | 1 | 3 | 11 | 4 | 7 | 0 | 2 | 2 | 2 | 2 | 18 | 0 | 0 | 0 | 0 | 103 |
| Phase 3 — Black or African American | 0 | 0 | 0 | 15 | 54 | 61 | 3 | 16 | 32 | 2 | 3 | 2 | 5 | 16 | 10 | 7 | 2 | 52 | 0 | 0 | 0 | 0 | 280 |
| Phase 3 — Multiple | 0 | 0 | 0 | 1 | 6 | 6 | 1 | 3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 8 | 0 | 0 | 0 | 0 | 28 |
| Phase 3 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
| Phase 3 — White | 0 | 0 | 0 | 252 | 247 | 240 | 100 | 79 | 61 | 104 | 92 | 87 | 99 | 15 | 21 | 80 | 37 | 372 | 0 | 0 | 0 | 0 | 1886 |
| Phase 3 — Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 3 — Not Reported | 0 | 0 | 0 | 33 | 44 | 49 | 0 | 1 | 6 | 10 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 151 |
| Phase 3 — Unknown | 0 | 0 | 0 | 4 | 8 | 2 | 0 | 6 | 3 | 0 | 1 | 2 | 0 | 0 | 1 | 23 | 22 | 10 | 0 | 0 | 0 | 0 | 82 |
| Phase 3 - Exploratory — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 3 - Exploratory — Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 3 - Exploratory — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 3 - Exploratory — Multiple | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 3 - Exploratory — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 3 - Exploratory — White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 3 - Exploratory — Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 3 - Exploratory — Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 8 | 9 | 28 |
| Phase 3 - Exploratory — Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Feb 2021 to primary completion in Jun 2023, 28 months.
Results were first posted in Sep 2025, 2 years 2 months after primary completion. A results delay was requested in Jun 2024.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 28 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →